60717-45-5

Usage

Uses

Used in Pharmaceutical Research:
N-Methyl-1-(phenylmethyl)-3-piperidinamine serves as a crucial building block in the development of new pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of various drug candidates, particularly those targeting the central nervous system.
Used in Organic Synthesis:
As an organic synthesis building block, N-Methyl-1-(phenylmethyl)-3-piperidinamine is utilized in the creation of a wide range of organic compounds. Its versatility in chemical reactions makes it valuable for the production of specialty chemicals and intermediates in the chemical industry.
Used in Pain Management:
N-Methyl-1-(phenylmethyl)-3-piperidinamine has been studied for its potential use in pain management. Its structure and properties suggest that it may have applications in the development of analgesics, offering a new avenue for the treatment of various types of pain.
Used in Central Nervous System Disorders Treatment:
N-Methyl-1-(phenylmethyl)-3-piperidinamine has also been investigated for its potential therapeutic effects on central nervous system disorders. Its interaction with specific neurological pathways could make it a candidate for the development of treatments for conditions such as Parkinson's disease, Alzheimer's disease, and other neurological disorders.

Upstream product

• 40114-49-6 1-benzyl-3-piperidone 
• 593-51-1 methylamine hydrochloride 
• 74-89-5 methylamine 

Downstream Products

• 172477-99-5 1-benzyl-3-<(t-butyloxycarbonyl)methylamino>-piperidine 
• 172477-95-1 1-benzyl-3-methylpropionylamino-piperidine 
• 172478-01-2 3-<(t-butyloxycarbonyl)methylamino>-piperidine 
• 172477-97-3 3-methylpropionylamino-piperidine 
• 172478-05-6 3-methylamino-1-propionyl-piperidine 

Relevant academic research and scientific papers

For the prevention and treatment of various autoimmune diseases of the new compound

Disclosed is an isoxazole derivative that inhibits the activity of the Janus kinases (JAKs), the structure thereof as presented in formula I, formula II, formula IX, and formula XI. The substituent groups in the formulas are described in the description. Also disclosed are the pharmaceutical composition of the compound and a related use in medicine preparation.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Monocyclic Analogues of the μ-Opioid Agonist 3,8-Diazabicyclooctanes: Synthesis, Modeling, and Activity

Several monocyclic derivatives structurally related to the μ-opioid agonist 3-cinnamyl-8-propionyl-3,8-diazabicyclooctane have been synthesized and tested in binding studies using the μ-selective 3H-DAMGO as ligand.Modeling studies have been performed on the same compounds in order to explain the observed lack of affinity towards μ-opioid receptors.

Pharmaceutical compositions and methods of inhibiting gastric acid secretion

Pharmaceutical compositions and methods of inhibiting gastric acid secretion by administering 1-(9-xanthenyl) amino-substituted-piperidines and pyrrolidines and new 1-(9-xanthenyl) amino-piperidine compounds.